Prospects of Risk-Sharing Agreements for Innovative Therapies in a Context of Deficit Spending in Bulgaria

Frontiers in Public Health

Georgi Iskrov¹ 

关键词: Bulgaria;    deficit spending;    drug budget;    innovative therapies;    uncertainty;    evidence;    risk-sharing;    health technology assessment;   

DOI  :  10.3389/fpubh.2015.00064

学科分类：卫生学

来源: Frontiers

【 摘 要 】

Innovative therapies are usually defined as newly introduced or modified health technologies with unproven effect or side effect undertaken in the best interest of the patient. These therapies could be situated at any point of the continuum: from genuine innovation with no precedent, to relative innovation representing a small variation from standard therapy, or using a conventional treatment in a different context (1). While the conception of innovative health technologies is not limited by therapeutic form (drugs, devices, procedures) or disease indication, innovative therapies are generally associated with expensive original drugs (2). Inclusion and provision of these therapies tend to be one of the most resource-consuming tasks for national health systems and payers.

【 授权许可】

CC BY